"But something much bigger could happen soon for Spectrum, and that is Melphalan. Melphalan is a type of chemotherapy that has been around since 1984. It's nothing new. Its annual global sales are $130 million. The problem is, in order to administer Melphalan, a chemical called propylene glycol is needed, and this chemical is known to poison the kidneys and cause cardiac trouble. It severely limits the dosage of Melphalan a cancer patient can take.
What Spectrum has is a new form of Melphalan that no longer needs propylene glycol as a delivery mechanism, upping the dosage patients can take in a sitting with less toxicity. In this case, you have a drug with an established sales record since the mid 1980s, reformulated and tested for bioequivalence already established; Orphan status granted; and a New Drug Application (NDA) to be submitted by the company next month.
Will Spectrum's new Melphalan be a blockbuster? No, but there is little reason that its new, less-toxic formulation of the same drug can't simply supplant MOST, OR PERHAPS EVEN ALL Melphalan sales."
1. $190 Million EXISTING Revenue Run Rate.
2. CE-Melphalan NDA imminent in next 2 months or so. Will DOMINATE $130 MILLION Market Annually per the STREET.
3. SPI-2012. $6 BILLION Annual Market with Same Sales Team that Launched Nuelasta (sp)
4. SPI-2012 Phase II Results IMMINENT.
5. SPI-2012 Phase III "GO - No Go" Imminent before year-end in next 3 or 4 months
6. Breakeven NON-GAAP Cash Flow from Operations. TODAY. TODAY other than Drug acquisition costs.
7. Apaziquone filing in early 2015. No bladder cancer drugs in 20 years. $250 MILLION Annual Peak Revenues if approved.
8. 19 Ongoing trials many of which involve MULTI-BILLION Markets including SPI-1620 for BREAST CANCER and Multiple Marqibo Studies.
OREX 50X revenues
ARNA 40X revenues
KERX 30X revenues
PCYC 17X revenues (although this may be a double opportunity... matrix may be right but too rich for me already)
AVNR 9X revenues
SLXP 8X revenues
SPPI 2X revenues Plus
Actually, you are too low imho.
6 to 8 times existing revenues at $190 MILLION per year. $18 PPS to $23 PPS. Pre- CE Melphalan and SPI-2012 Phase II Data.
Upcoming catalysts will catapult Spectrum into the ranks of a giant pharmaceutical of tomo...
Aug 16, 2014 3:20 PM by jwporegon2
8/17 1 7 hours ago
"Major downturn? Meltdown?
S&P500 will reach 2,030 by 12.31.2014
That represents a 4% increase over the S&P. If on TRIPLE MARGIN like shortshet trying to keep up with SPPI, he is DOWN 16 to 19% since July. Like his HANDLER SHORTS.
NINETEEN PERCENT. Now he acknowledges that if SPPI is at $8.32 then it BEATS the S&P and his predictions to year-end. Double it or triple the return irrelevant.
1. SPI-2012 Phase II.
2. CE-Melphalan NDA
3. Apaz NDA.
4. Apaz Phase III.
5. Q3 Revenues.
6. Phase II GO NO GO for SPI-2012.
Imbecile. Done. Finished.
HERE is your 15% DOWN:
1. Upro up to $110.31 from $109,76 on 7/31, Up 0.005%. Nothing.
2.. SPPI traded at $6.70 on 7/31 low. Now $7.98 PPS with an after hours HIGH of $8.09. Let's use $7.98 to help you. A NINETEEN PERCENT 19% Return This month in twelve days.
I was being generous YOU ARE DOWN 19% to SPPI this MONTH
Unless you want to go TRIPLE MARGINED to try to make up the difference. LMAO UPRO is TRIPLED MARGINED each direction.
S&P 4155 is your number apples to apples. LOL
Near term? Let me know when S&P is at 4155? Apples to Apples unless you go TRIPLE MARGIN both directions. And you are still down 15% this month.
You damx right I am serious. UPRO is itself margined. As a result you are investing (betting) on MARGIN. Yours or theirs is irrelevant. You are bettin triple margin up and TRIPLE MARGIN DOWN.
Yes, UPRO is STILL DOWN 15% to SPPI's Return in August.
He admitted it him/herself:
"S&P500 at 2,600 before SPPI hits $17 PPS?
UPRO = 3x S&P 35% increase
S&P up 35% before SPPI doubles?"
UPRO is margined at a 3 multiple. Wait till the downside.
SPPI went from a low of $6.70 to $7.98 in 12 days. Run your numbers Florida and Gtown dropout.
UPRO is TRIPLE MARGIN by definition. That is the investment parameters. It is "UPro".
Yes, UPRO is DOWN 15% to SPPI this MONTH.
Both are FACTS.
Keep Tracking. TRIPLE DOWNSIDE TOO.